Biomea Fusion
↗San Carlos, USA
Biomea Fusion is a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat metabolic diseases and genetically defined cancers. The company utilizes its proprietary FUSION™ System discovery platform to engineer irreversible small molecule drugs that form permanent bonds with target proteins, potentially offering superior selectivity and more durable therapeutic responses compared to conventional reversible drugs.
In early 2025, the company underwent a strategic realignment to prioritize its metabolic disease programs, specifically focusing on its lead candidate icovamenib (BMF-219) for diabetes and BMF-650 for obesity. This shift included a workforce reduction and the deprioritization of internal oncology development to extend the company's cash runway and focus on high-impact metabolic therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$209M
Investors:FMR LLC, Vanguard Group, Aisling Capital Management, Woodline Partners, Marshall Wace, BlackRock
STOCK
Exchange:NASDAQ
Ticker:BMEA
Market Cap:$105M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2b
Modalities:Small molecule, Covalent inhibitors
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:J&J Labs (Early discovery of BMF-219), Contract Manufacturing Organizations (Outsourced API production)
COMPETITION
Position:Emerging
Competitors:Altimmune, Viking Therapeutics, Kura Oncology, Syndax Pharmaceuticals, Eli Lilly (GLP-1 space)
LEADERSHIP
Key Executives:
Mick Hitchcock, Ph.D. - Interim CEO
Thomas Butler - Co-founder & Former CEO
Scientific Founders:Thomas Butler, Ramses Erdtmann
Board Members:Mick Hitchcock, Thomas Butler, Sowmya Kaur
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biomea Fusion. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.